Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 32, Issue 4, 2003, Pages 439-442

  Kojima, R ^a   Kami, M ^a   Kim, S W ^a   Murashige, N ^a   Kishi, Y ^a   Hori, A ^a   Imataki, O ^a   Hamaki, T ^a   Sakiyama, M ^a   Masuo, S ^b   Fujisawa, Y ^a   Makimoto, A ^a   Heike, Y ^a   Tanosaki, R ^a   Takaue, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JR Tokyo General Hospital   (Japan)

Author keywords

Graft versus autoimmunity effect; Graft versus host disease; Psoriasis; Reduced intensity stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISOLONE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHIMERA; CLINICAL FEATURE; DISEASE COURSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PSORIASIS; RASH;

AGED; CYCLOSPORINE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; METHOTREXATE; PSORIASIS; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 10744224648     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704146     Document Type: Article

References (16)

1. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
2. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768-784.
3. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int J Hematol 2002; 76 (Suppl 1): 226-247.
4. Snowden JA, Biggs JC, Milliken ST et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthr Rheum 1999; 42: 2286-2292.
5. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases (SADS). New perspectives, new problems. Haematologica 2000; 85 (Suppl): 71-80.
6. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 2001; 86: 337-345.
7. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853-857.
8. Saito T, Kanda Y, Kami M et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014-1020.
9. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
10. Chakrabarti S, Handa SK, Bryon RJ et al. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant? Transplantation 2001; 72: 340-342.
11. Adkins DR, Abidi MH, Brown RA et al. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy. Bone Marrow Transplant 2000; 26: 1239-1241.
12. Spitzer TR, Sykes M. Treatment of renal-cell cancer by transplantation of allogeneic stem cells. N Engl J Med 2001; 344: 137-138.
13. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
14. Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
15. Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pre transplantation and post transplantation factors on outcome. J Clin Oncol 2001; 19: 3340-3349.
16. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-350.